Phase II Study of Eloxatin+5-FU/LV in Patients With Unresectable Hepatocellular Carcinoma

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2010

Conditions

Carcinoma, Hepatocellular

Interventions

DRUG

Oxaliplatin

85mg/m², 2 hours IV infusion, Day 1; Every 2 weeks

DRUG

Fluorouracil

400mg/m², 2 hours IV bolus, Day 1; 22 hours continuous IV infusion 600mg/m², Day 1 and Day 2; Every 2 weeks

DRUG

Leucovorin

200mg/m², Day 1 and Day 2; Every 2 weeks

Trial Locations (1)

Sanofi-Aventis Administrative Office, Seoul